Category: Nevin Manimala

J Perianesth Nurs. 2025 Jun 11:S1089-9472(25)00056-5. doi: 10.1016/j.jopan.2025.02.018. Online ahead of print.

ABSTRACT

PURPOSE: This study was conducted to examine the effect of operating room waiting time on surgical fear and preoperative anxiety in patients undergoing urinary system surgery.

DESIGN: This study was conducted as a comparative cross-sectional.

METHODS: This study was conducted with 150 patients undergoing urinary system surgery at a state hospital in Turkey between December 2023 and July 2024. Data were collected using a Descriptive Characteristics Form, the Visual Analog Scale, and the Surgical Fear Questionnaire at two time points: before entering the operating room (T0) and before being placed on the surgical table (T1). Patients were divided into 2 groups based on waiting time: group A (<30 minutes) and group B (≥30 minutes). Statistical analysis was performed with SPSS 27.0 at a significance level of P less than .05.

FINDINGS: Patients in groups A and B were similar in terms of descriptive characteristics and T0 assessment. However, at T1 assessment, patients in group B had significantly higher levels of anxiety (P = .002), short-term fear (P = .001), and total fear (P = .001) compared to group A. Waiting time had a significant effect on anxiety (β = 0.637, P = .001), short-term fear (β = 0.788, P = .001), and total fear (β = 0.536, P = .001).

CONCLUSIONS: Prolonged waiting time in the operating room significantly increases psychological burden by significantly increasing anxiety, short-term fear, and total fear levels in patients.

PMID:40498427 | DOI:10.1016/j.jopan.2025.02.018

Dig Dis Sci. 2025 Jun 11. doi: 10.1007/s10620-025-09111-x. Online ahead of print.

ABSTRACT

BACKGROUND: The Viral Hepatitis National Strategic Plan documents the value of a collaborative provider workforce trained in the provision of hepatitis treatment and prevention to facilitate the United States’ 2030 viral hepatitis elimination efforts.

AIMS: This study aims to characterize the amount and type of viral hepatitis education topics provided to Doctor of Medicine students during the preclinical phase of medical school.

METHODS: Investigators developed a 19-item Qualtrics survey and sent survey links to curricula content experts at 157 accredited medical colleges/schools in April-May 2023, and allotted 28 days for survey completion. Survey questions assessed the type, amount, and topics of viral hepatitis instruction provided to Doctor of Medicine students, and the hepatitis instructors’ training/experience. We used descriptive statistics for analysis.

RESULTS: 51 medical institutions across 22 jurisdictions responded; 90% of programs presented hepatitis education as a required part of the curriculum. All education topic respondents confirmed that their institutions provided instruction on viral hepatitis epidemiology, diagnostics, and HBV vaccination. Screening and linkage to care for HBV, HCV, and HDV were included in 69%, 78%, and 33% of curricula, respectively, while 11% of curricula discussed national efforts to eliminate hepatitis by 2030.

CONCLUSIONS: Survey results show similarities, variability, and gaps in topics devoted to viral hepatitis education across United States medicine curricula. Most programs required hepatitis education in their curricula, many discussed HBV and HCV screening, and few discussed hepatitis elimination. To support national viral hepatitis elimination efforts, ideally, all medical schools should provide education on (1) screening, (2) linkage to care, and (3) national elimination strategies to better equip all future physicians to work toward viral hepatitis elimination.

PMID:40498408 | DOI:10.1007/s10620-025-09111-x

Dermatol Ther (Heidelb). 2025 Jun 11. doi: 10.1007/s13555-025-01456-5. Online ahead of print.

ABSTRACT

INTRODUCTION: Psoriasis body surface area (BSA) of 10% or more has been a major criterion for determining systemic therapy eligibility. However, patients with BSA < 10% and even ≤ 3% may have high disease burden and difficulties accessing biologics. To assess psoriasis burden among patients with BSA ≤ 10%, this study characterized patient-reported outcomes (PROs) across BSA categories among systemic treatment-naïve patients initiating biologic therapy.

METHODS: Patients from the CorEvitas Psoriasis Registry initiating biologics between April 2015 and September 2023 were categorized according to low (< 3%), medium (3-10%), or high (> 10%) BSA involvement. Measures assessed at initiation of biologic therapy included health-related quality of life, itch, pain, fatigue, psoriatic arthritis, psoriasis disease characteristics, and medical history. Overlap between BSA groups for each outcome was calculated via non-parametric Mann-Whitney statistic transformation (range 0.0-1.0; 0.5 indicates complete similarity [i.e., for a comparison between low and high BSA groups, overlap of 0.5 means there is 50% probability that a randomly selected patient with low BSA would have the same or greater PRO burden as one with high BSA]; 0 or 1 indicates complete dissimilarity) to determine whether each measure differed in randomly selected patients with low or medium versus high BSA.

RESULTS: Of 1640 patients who initiated biologics, 7.0% had low BSA, 46.9% had medium BSA, and 46.2% had high BSA involvement. PRO overlap statistics ranged from 0.52 to 0.59 and from 0.60 to 0.70 for randomly selected patients with high versus medium and low BSA, respectively, indicating patients with high and medium BSA are likely to have similar levels of disease burden, and patients with high BSA are slightly more likely to have higher disease burden than those with low BSA. Near complete overlap (range 0.44-0.58) was observed for psoriasis disease characteristics and medical history in the low versus high and medium BSA groups.

CONCLUSION: Observed overlap in PROs across BSA categories shows that patients with low BSA can experience similarly poor quality of life and high symptom burden to those with higher BSA. These findings support the appropriateness of considering biologic therapies for patients with low BSA and indicators of high disease burden.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT02707341.

PMID:40498388 | DOI:10.1007/s13555-025-01456-5

Dermatol Ther (Heidelb). 2025 Jun 11. doi: 10.1007/s13555-025-01447-6. Online ahead of print.

ABSTRACT

INTRODUCTION: The skin aging process is mainly associated with the appearance of fine wrinkles and flaccid, dry, and dull skin. A hyaluronic acid matrix (HAm) ingredient containing HA, sulfated glycosaminoglycans (GAGs), and collagen is proposed to enhance skin health by improving hydration and structural integrity. The objective of this study was to evaluate the impact of oral supplementation with HAm on skin properties.

METHODS: A 12-week, randomized, double-blind, placebo-controlled trial was designed, including 60 healthy women aged 35-65 with signs of natural skin aging (NCT05813054). Participants were assigned to receive either HAm (Dermial^®; 60 mg daily) or a placebo and were dermatologically assessed after 6 and 12 weeks. Skin properties were determined by the evaluation of stratum corneum hydration (SCH), brightness/glow, wrinkles, dryness, roughness, smoothness, pH, temperature, elasticity, friction, antioxidant capacity, deformability, melanin index, and erythema index. In addition, global satisfaction and adverse reactions were assessed.

RESULTS: Assessments were performed on data from 50 participants as a per-protocol analysis. Skin wrinkles and smoothness (6 weeks), and roughness (12 weeks) significantly improved in the HAm group compared with the placebo group. Participants receiving HAm had significantly increased skin SCH and brightness, and decreased scaliness and temperature at 6 and 12 weeks versus the baseline value. A statistically significant reduction in the erythema index and a balanced pH were also observed in the HAm group. Global satisfaction was significantly higher in HAm as compared to placebo. No serious adverse events associated with the tested products were registered during the study.

CONCLUSIONS: Daily supplementation with HAm effectively improves multiple aspects of skin health and appearance, suggesting its potential as a safe and beneficial antiaging ingredient. These results support the role of HAm in promoting skin brightness/glow and hydration, and reducing the visible effects of aging.

TRIAL REGISTRATION: ClinicalTrials. gov identifier, NCT05813054.

PMID:40498387 | DOI:10.1007/s13555-025-01447-6

Acta Parasitol. 2025 Jun 11;70(3):131. doi: 10.1007/s11686-025-01072-5.

ABSTRACT

PURPOSE: The genus Myobia (Acari: Myobiidae) includes obligate ectoparasites of rodents, with M. murismusculi being the most frequently reported species in laboratory mouse colonies worldwide. However, morphological overlap and nomenclatural confusion have long hindered accurate species identification. This study aims to describe a new fur mite species from Mus musculus and to distinguish it from M. murismusculi and related taxa using detailed morphological and morphometric analyses.

METHODS: Fur mites were collected from laboratory mice in two facilities and examined using light and scanning electron microscopy. Morphological characters were described, measured, and illustrated. Sstandardized morphometric characters were analyzed across multiple Myobia species using principal component analysis (PCA) and permutational multivariate analysis of variance (PERMANOVA) to assess interspecific variation and species boundaries.

RESULTS: The new species, Myobia murina sp. nov., differs from M. murismusculi by longer dorsal setae ve and si. PCA and t-SNE analyses revealed a distinct cluster for M. murina, and PERMANOVA confirmed significant morphological divergence from all examined congeners (R² = 0.873, p < 0.001). An updated identification key for female mites of the subgenus Myobia is also provided.

CONCLUSION: This study demonstrates the utility of morphometric approaches in mite taxonomy and confirms M. murina sp. nov. as a morphologically and statistically distinct species. Accurate species identification is essential for laboratory animal health management and fur mite diagnostics.

PMID:40498371 | DOI:10.1007/s11686-025-01072-5

Cancer Metastasis Rev. 2025 Jun 11;44(2):54. doi: 10.1007/s10555-025-10268-0.

ABSTRACT

There is abundant but discrepant scientific literature reporting an effect of opioids on the course of cancer. The International Agency for Research on Cancer monographs recently classified opium consumption as carcinogenic to humans in certain organs, raising concerns this may be due at least in part to the alkaloids opium contains (such as morphine and codeine). This systematic review investigated whether opioid exposure among cancer-free individuals is independently associated with the risk of future cancer incidence or cancer mortality. An electronic database search was conducted in PubMed, EMBASE, Web of Science, PsycINFO, International Pharmaceutical Abstracts, CINAHL and Scopus. Studies were included if they provided a statistical estimate of cancer mortality, cancer incidence, or cancer risk following opioid exposure. Study quality was assessed using the Newcastle-Ottawa Scale. Study characteristics and outcomes were extracted and analysed in a descriptive narrative synthesis. There were 27 studies that met the inclusion criteria, representing a total of 4,542,745 participants. Twelve of the 27 were rated as high quality according to the Newcastle-Ottawa Scale. The observed data is consistent with a small increase in the risk of cancer incidence or cancer mortality following opioid exposure, particularly in a subset of organs. There is, however, considerable uncertainty in the evidence given the substantial risk of bias in estimating the overall effect of opioid exposure on cancer outcomes in these studies. This review synthesises studies reporting cancer risk following opioid exposure and identifies the key methodological factors influencing ongoing uncertainty estimating the true effect. Rigorous epidemiological studies employing specific methods to minimize bias are warranted.

PMID:40498363 | DOI:10.1007/s10555-025-10268-0

Exp Appl Acarol. 2025 Jun 11;95(1):10. doi: 10.1007/s10493-025-01035-5.

ABSTRACT

This study assessed the efficacy of a plant-based premix of feed additives (PFA) composed of essential oils and vitamins on a farm with 1560 laying hens (ISA Brown line), naturally infested with poultry red mite (PRM), Dermanyssus gallinae. The trial lasted 44 days. The AVIVET traps were used to determine PRM mass, number of eggs, larvae, blood-engorged and unfed nymphs, and adults on day – 12, – 5, and 0 before, and on days 2, 5, 8, 11, 15, 23, and 30, after, hens started to consume PFA. Friedman’s ANOVA was utilised to identify differences between means, and the post hoc Wilcoxon matched Pairs Test was then employed to ascertain the impact of the tested PFA on the D. gallinae population. From the eighth day until the end of the trial period, a statistically lower mass of mites (P < 0.05), the number of nymphs (P < 0.05) and the number of blood-engorged mites (P < 0.05) were observed compared to day 0. In comparison to day 0, a statistically significantly lower number of eggs (P < 0.01) was observed on day 5 (P < 0.05), day 11 (P < 0.01), larvae on day 23 (P < 0.05) and day 30 (P < 0.01), as well as unfed mites on days 15, 23, and 30 (P < 0.01, P < 0.01 and P < 0.001, respectively). Egg production (%, hen-day) in 52-54 weeks of age (control period) was 88.7, while in 55-58 weeks of age (trial period) was 89.5. The results indicate that the tested PFA can control PRM without adversely affecting egg production.

PMID:40498361 | DOI:10.1007/s10493-025-01035-5

Eur J Trauma Emerg Surg. 2025 Jun 11;51(1):226. doi: 10.1007/s00068-025-02896-6.

ABSTRACT

PURPOSE: Accurate trauma triage ensures timely and specialized care for potentially critically injured patients. Undertriage remains a concern, particularly for patients without obvious vital sign derangements. This study evaluates the potential of biomarkers such as lactate, base deficit (BD), and blood glucose to improve triage score accuracy in identifying patients with severe injuries (Injury Severity Score [ISS] > 15) and predicting intensive care unit (ICU) admission without a high risk of severe injury (HRSI).

METHODS: This retrospective, single-center cohort study (2017-2021) included trauma patients with trauma team activation (TTA) due to mechanism of injury(MOI) and therefore only patients with moderate risk of severe injury criteria(MRSI). Exclusion criteria were any HRSI-criterion such as advanced airway management, Glasgow Coma Scale < 12, systolic blood pressure < 90 mmHg, and specific injury patterns. Biomarkers were collected upon emergency department (ED) admission. Logistic regression and receiver operating characteristic (ROC) curve analyses evaluated biomarker predictive value alone and in combination with existing triage scores.

RESULTS: The study population included 3371 TTAs of which we were able to include 302 in our study-group. 15% had ISS > 15. These patients had significantly higher lactate (2.38 ± 1.2 vs. 1.57 ± 0.75 mmol/L, p < 0.05), BD (-0.2 ± 5.0 vs. 1.7 ± 2.7 mmol/L, p < 0.05), and blood glucose (144.8 ± 46.0 vs. 118 ± 37.9 mg/dL, p < 0.05). Augmenting triage scores with lactate improved predictive accuracy, with the highest AUC (0.774) observed for the age-lactate model. ICU admission prediction was less robust (AUC = 0.674).

CONCLUSION: Our findings suggest that biomarkers such as lactate could strengthen trauma triage scores, but prospective, multicenter validation is essential to confirm these preliminary results.

PMID:40498359 | DOI:10.1007/s00068-025-02896-6

Womens Health (Lond). 2025 Jan-Dec;21:17455057251329640. doi: 10.1177/17455057251329640. Epub 2025 Jun 11.

ABSTRACT

BACKGROUND: Violent and abusive behavior in relationships causes immense individual and community harm. Mapping the emergence of different types of abuse over time and recognising behavioral patterns, could enable more targeted intimate partner violence (IPV) prevention, screening, and early intervention. While there has been some qualitative research into early warning signs of abuse and escalating homicide risks in relationships, no known studies have asked a large sample of survivors to document the sequence of abusive behaviors in a recent relationship.

OBJECTIVES: To explore timelines of psychologically, physically, and sexually abusive behaviors and life events in a recent relationship (during the last 5 years) to create a macro timeline of abuse.

DESIGN: Cross sectional survey of a nationally representative sample (gender, age, state, locality).

DATA SOURCES AND METHODS: Eight hundred and fifteen Australian IPV women survivors.

RESULTS: Results indicated that psychological abuse was a feature of most violent relationships, and almost always underpinned physical and sexual abuse. Psychological abuse often began before couples moved in together, while physical and sexual abuse came later. The earliest indicators for survivors that something was wrong was being isolated from others and feeling controlled by their partner. For many survivors, growing concern about the impact of abuse on their children occurred around the same time as leaving their relationship and trying to get help.

CONCLUSION: Findings indicate a pattern of escalating behaviors over the course of a relationship that are consistent with the concept of coercive control. The macro timeline contains important learnings for intervening early with future survivors.

PMID:40498352 | DOI:10.1177/17455057251329640

Langenbecks Arch Surg. 2025 Jun 11;410(1):186. doi: 10.1007/s00423-025-03773-x.

ABSTRACT

BACKGROUND: Treatment options for intracranial atherosclerotic stenosis (ICAS) are limited, but endovascular intervention has gained increasing attention in recent years.

AIM: To evaluate the safety and efficacy of the Neuroform EZ stent for treating ICAS in the posterior circulation.

MATERIAL & METHODS: Patients’ (n = 50) eligibility depended on ICAS with severe stenosis (≥ 70%) in the intracranial segment of the vertebral artery or basilar artery shown by cerebral angiography. General information of the participants were recorded, Adverse events during the perioperative period were observed, including in-stent thrombosis, postoperative hyperperfusion, stroke, and mortality. Before the procedure, neurological deficits (NIHSS score) and neurological recovery (mRS score) were recorded at 12 months postoperatively. The degree of vascular stenosis was evaluated prior to and following the procedure, and in-stent restenosis (ISR) was recorded at 12 months post-operation.

RESULTS: Fifty-two stents were successfully placed in 50 patients, followed by standardized medication. Angiographic follow-up was completed 12-months postoperatively, and there was only one case of ISR (4.35%) was observed. Postoperative stenosis of responsible vessel was significantly relieved (77.98 ± 7.69 vs. 33.85 ± 9.11), with statistically significant differences (P < 0.01). The extent of neurological deficits and effects on daily living activities at 12 months postoperatively exhibited significant improvements, as evidenced by NIHSS scores (2.40 ± 1.37 vs. 0.82 ± 0.77) and mRS scores ≤ 2 (82.0% vs. 98.0%) (P < 0.01). Cerebral perfusion improved, with no significant perioperative complications.

CONCLUSIONS: The Neuroform EZ stent is a safe and effective treatment approach for ICAS in the posterior circulation.

PMID:40498346 | DOI:10.1007/s00423-025-03773-x